B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile

Abstract

Patients with type 2 diabetes (T2D) have disease-associated changes in B-cell function, but the role these changes play in disease pathogenesis is not well established. Data herein show B cells from obese mice produce a proinflammatory cytokine profile compared with B cells from lean mice. Complementary in vivo studies show that obese B cell-null mice have decreased systemic inflammation, inflammatory B-and T-cell cytokines, adipose tissue inflammation, and insulin resistance (IR) compared with obese WT mice. Reduced inflammation in obese/insulin resistant B cell-null mice associates with an increased percentage of anti-inflammatory regulatory T cells (Tregs). This increase contrasts with the sharply decreased percentage of Tregs in obese compared with lean WT mice and suggests that B cells may be critical regulators of T-cell functions previously shown to play important roles in IR. We demonstrate that B cells from T2D (but not non-T2D) subjects support proinflammatory T-cell function in obesity/T2D through contact-dependent mechanisms. In contrast, human monocytes increase proinflammatory T-cell cytokines in both T2D and non-T2D analyses. These data support the conclusion that B cells are critical regulators of inflammation in T2D due to their direct ability to promote proinflammatory T-cell function and secrete a proinflammatory cytokine profile. Thus, B cells are potential therapeutic targets for T2D.immunometabolism | lymphocytes M ultiple studies support the concept that inflammation strongly associates with insulin resistance (IR), which, in addition to loss of islet function, defines type 2 diabetes (T2D) (1). Work implicating B cells in IR/T2D is limited. We showed B cells from T2D subjects secrete a proinflammatory cytokine profile, including an extraordinary inability to secrete the potent anti-inflammatory cytokine IL-10 and an elevated production of proinflammatory IL-8 compared with B cells from non-T2D subjects (2). Given the importance of B-cell IL-10 in preventing numerous inflammatory diseases (3, 4) and the links between IL-8 and T2D (5, 6), these data suggest that altered B-cell cytokine production plays an important role in initiating or promoting IR/T2D. Published analyses further support a role for B cells in IR and include studies of B cell-null New Zealand Obese (NZO) mice, which, in contrast to B cell-sufficient NZOs, fail to develop IR in response to obesity (7). These findings have been recently reproduced in studies showing obese B cell-null or B cell-depleted mice have less inflammation and IR than obese WT mice (8). Interestingly, T-cell cytokine production is decreased in obese B cell-null mouse adipose tissue (AT) (8), which raises the possibility that, in addition to production of a proinflammatory cytokine profile, B cells may function in IR by regulating the T cell-mediated inflammation known to drive disease pathogenesis (9, 10). We identified a proinflammatory T-cell ratio [defined by increased Th17 cells plus decreased regulatory T cells (Tregs)] in T2D patients that mirror...

Expanded autologous adipose derived stem cell transplantation for type 2 diabetes mellitus

“…These studies showed that if depletion of CD11c + macrophages or inhibition of macrophage recruitment via MCP-1 knockout in obese mice could significantly reduce inflammation and increase insulin sensitivity (Kamei et al, 2006;Kanda et al, 2006;Patsouris et al, 2008). Increasing evidence in animals and humans about inflammation-induced insulin resistance in T2D were provided, and included abnormalities of lymphocytes (DeFuria et al, 2013;Winer et al, 2011), neutrophils (Talukdar et al, 2012), eosinophils , mast cells (Liu et al, 2009) and dendritic cells (Musilli et al, 2011). Therefore, the biggest challenge for treatment of T2D was modifying these immune cells to repair the insulin resistance.…”

Increased fat cell size: a major phenotype of subcutaneous white adipose tissue in non-obese individuals with type 2 diabetes

“…Obesity promotes changes in adipose tissue metabolism, such as increased rate of spontaneous (basal) lipid mobilisation (lipolysis) from fat cells, as well as alterations in populations of adipose tissue-residing immune cells. Data in both animal models [1,2] and human obese WAT [3,4] have suggested an increased recruitment and/or differentiation of pro-inflammatory immune cell types (predominantly M1 macrophages) and also, albeit to a less pronounced degree, Electronic supplementary material The online version of this article (doi:10.1007/s00125-015-3810-6) contains peer-reviewed but unedited supplementary material, which is available to authorised users.…”

CD40 promotes MHC class II expression on adipose tissue macrophages and regulates adipose tissue CD4+ T cells with obesity

“…The emerging concept that activation of the adaptive immune system links obesity to metabolic disease has led our group and others to examine the role of leukocyte cross talk in adipose tissue inflammation [14,[40][41][42][43]. T cell costimulation is important in APC-T cell communication, and these signals are often critical nodes in the regulation of both T reg and effector/ memory T conv activity and homeostasis [18,44,45].…”